von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations of the VHL gene. Recent studies suggest that VHL protein (pVHL) is a component of an E3 ubiquitin ligase, but the detailed biological function of pVHL remains to be determined. To further elucidate the biological functions of pVHL, we searched pVHL-interacting proteins using yeast twohybrid screening. A novel protein named VHL-interacting deubiquitinating enzyme 1 (VDU1) was identified as being able to directly interact with pVHL in vitro and in vivo. We have determined the full-length cDNA of this enzyme, which includes two putative subtypes. Type I consists of 942 amino acids, and type II consists of 911 amino acids with predicted molecular masses of 107 and 103 kDa, respectively. We have also cloned a mouse homologue of this enzyme. Sequence analysis reveals that this protein is conserved between human and mouse and contains the signature motifs of the ubiquitin-specific processing protease family. Enzymatic function studies demonstrate its deubiquitinating activity. We have determined that the VDU1-interacting region in pVHL is located in its ␤-domain, and several naturally occurring mutations located in this domain disrupt the interaction between pVHL and VDU1 protein. Co-immunoprecipitation demonstrates that VDU1 can be recruited into the pVHL-elongin C-elongin B complex. Finally, we demonstrate that VDU1 is able to be ubiquitinated via a pVHL-dependent pathway for proteasomal degradation, and VHL mutations that disrupt the interaction between VDU1 and pVHL abrogate the ubiquitination of VDU1. Our findings indicate that VDU1, a novel ubiquitin-specific processing protease, is a downstream target for ubiquitination and degradation by pVHL E3 ligase. Targeted degradation of VDU1 by pVHL could be crucial for regulating the ubiquitinproteasome degradation pathway.
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von Hippel-Lindau (VHL) 1 disease is a rare autosomal dominant disorder that predisposes affected individuals to a variety of tumors including hemangioblastomas in the central nervous system and retina, clear cell carcinomas of kidneys, pheochromocytomas of adrenal glands, cysts and/or adenomas and islet cell tumors of the pancreas, cystadenomas of the epididymis, and endolymphatic sac tumors of the inner ear (1) . VHL gene mutations can be detected in 100% of patients who carry a clinical diagnosis of VHL disease (2) . More importantly, the VHL gene is inactivated in ϳ50 -80% of the more common sporadic form of renal clear cell carcinoma (3) (4) (5) . VHL protein (pVHL) has been demonstrated to associate with elongin C (EC), elongin B (EB), and cullin-2 (CUL-2) in a complex termed VCB-CUL-2 (6 -8) . This multi-protein complex exhibits structural and functional similarity to SCF (Skp1/Cdc53 or cullin/ F-box) ubiquitin ligases (6 -11) . The ubiquitin-proteasome degradation system has been shown to control the abundance and activity of oncogene and tumor suppressor gene products, transcription factors, and other signaling molecules (12, 13) . The crucial substrate recognition step in ubiquitin-dependent proteolysis is mediated by the diverse family of E3 ubiquitin ligases. pVHL contains two domains (␣-domain and ␤-domain) (14) . Whereas the ␣-domain serves as the EC binding site, the ␤-domain plays a role in substrate recognition (6 -11, 14) . Recent studies revealed that hypoxia-inducible factor, HIF1-␣, is a substrate of VCB-CUL-2 E3 ligase for ubiquitination and degradation at normoxia via physical interaction with the core of the oxygen-dependent degradation domain (15, 16) . HIF1 is a sequence-specific DNA binding transcriptional complex consisting of an ␣-subunit and a ␤-subunit that regulates genes involving angiogenesis (17, 18) . Without functional pVHL, HIF1 can be accumulated in cells resulting in overexpression of HIF1 target genes such as vascular endothelial growth factor (11) . Hemangioblastomas are mainly formed by excessive growth of blood vessels responding to a local increase of angiogenic factors (19, 20) . These factors are secreted by poorly understood stromal cells bearing the mutant VHL gene. Indeed, it has been demonstrated that the overexpression of vascular endothelial growth factor in a mouse brain is enough to induce blood vessels to proliferate and generate a structure similar to a hemangioblastoma (21) . Tumorigenesis in renal cells seems to be more complex because, although loss of the VHL gene has been seen in early premalignant renal cysts, accumulation of other mutations or derailed molecule events are necessary for a full-blown clear cell renal carcinoma (22) . Besides HIF1-␣, other important downstream targets of VCB-CUL-2 E3 ubiquitin ligase might exist. It is important to identify other pVHL-ubiquitinating targets or pVHL-interacting proteins, which may further reveal the molecular mechanisms of pVHL-related tumorigenesis.
In this report, we have identified a novel pVHL-interacting protein that belongs to the ubiquitin-specific processing protease (USP) family. We have named this protein as pVHL-interacting deubiquitinating enzyme 1 (VDU1). Cloning the fulllength cDNAs of human VDU1 (hVDU1) and its mouse homologue (mVDU1) has revealed that this protein is highly conserved between human and mouse and contains the signature motifs of the USP family. Enzymatic function studies demonstrate its deubiquitinating activity. We have determined that the VDU1-interacting region in pVHL is located in the ␤-domain of pVHL, which is the region harboring naturally occurring mutations in VHL disease and target recognition domain for ubiquitin-dependent degradation pathway. Several naturally occurring mutations located in the ␤-domain of pVHL disrupt the interaction between pVHL and VDU1 protein.
Coimmunoprecipitation assays demonstrate that hVDU1 can be recruited into the VCB complex. Finally, we demonstrate that hVDU1 can be ubiquitinated for degradation in a pVHL-dependent manner, and VHL mutations that disrupt the interaction between hVDU1 and pVHL abrogate the ubiquitination of hVDU1. Our current findings indicate that VDU1 is a downstream target of pVHL for ubiquitination and degradation.
MATERIALS AND METHODS
Yeast Two-hybrid Screening-Yeast two-hybrid system 3 (CLON-TECH), an improved GAL4-based system, was used in our experiments. A pretransformed human kidney cDNA library (pACT2 vector) in the Tyr-187 yeast strain was screened via yeast mating with a yeast strain AH109 transformed with a VHL bait construct pGBKT7-hVHL19. This construct, prepared to express a fusion protein containing GAL4 DNA binding domain and pVHL amino acids 54 -213, was verified by DNA sequencing. The expression of GAL4-hVHL19 fusion protein in yeast strain AH109 was confirmed by Western blotting. This bait did not have any intrinsic activation function as demonstrated by a bait-testing assay. A stringent selection procedure detecting only strong interactions was used in our experiments.
RACE-PCR and Sequence Analysis-The 5Ј-and 3Ј-RACE (rapid amplification of cDNA end) experiments were performed using Marathon cDNA amplification kit (CLONTECH) according to the protocol by the manufacturer. The specific PCR reaction conditions were 94°C for 3 min; 5 cycles of 94°C for 5 s, 72°C for 3 min; 5 cycles of 94°C for 5 s, 70°C for 3 min; and then 25 cycles of 94°C for 5 s, 68°C for 3 min. The PCR products were subcloned into pCR2.1 vector (Invitrogen), and selected clones were sequenced to assemble the full-length cDNA. Online BLAST searches were performed using the GenBank TM data base via the National Center for Biotechnology Information (NCBI) home page on the world wide web. Open reading frame and translated protein sequences were analyzed by MacDNASIS software (HITACHI) and data base searches.
Plasmid Construction-To express GST fusion protein, pGEX6p1-VHL19 was constructed by inserting human pVHL19 cDNA into pGEX6p1 vector (Amersham Biosciences, Inc.). pGEX6p1-VHL-(54 -83), pGEX6p1-VHL-(54 -100), pGEX6p1-VHL-(80 -213), and pGEX6p1-VHL-(93-213) derived from pGEX6p1-VHL19 were constructed to express pVHL fragments containing residues 54 -83, 54 -100, 80 -213 and 93-213, respectively. Missense mutation constructs pGEX6p1-VHL19-F76I, N78S, P81S, R82P, P86H, R167W, and R167Q were derived from pGEX6p1-VHL19 by PCR-based site-directed mutagenesis. pCMX-VHL19 was constructed for FLAG-tagged pVHL. pcDNA4c-VHL19, pcDNA4c-VHL19-P81S, and pcDNA4c-VHL19-R82P were constructed for in vitro transcription and translation. Because the N terminus of hVDU1 Type I is not conserved in mouse, pSG5-hVDU1 and pcDNA4c-hVDU1 were prepared for expressing hVDU1 Type II without or with 6ϫ His tag, respectively. pM-VHL19 and pVP16-hVDU1 were prepared for mammalian two-hybrid assay. pET28c-hVDU1 was prepared to express 6ϫ His tag-fused hVDU1 in Escherichia coli. pD-EST14-hVDU1 and pDEST17-hVDU1 were prepared to express native hVDU1 and 6ϫ His tag-fused hVDU1 in E. coli, respectively. pEGFP-C3-hVDU1 was constructed to express GFP-hVDU1 fusion protein.
pGEX-3X-Ub and pACYC-184-Ub-GST were prepared to express ubiquitin C terminus fused with GST (deubiquitinating substrate) in E. coli. pcDNA3-EB and pcDNA4-EC were constructed to express elongin B and 6ϫ His-fused elongin C for co-immunoprecipitation. pSG5-p53 was constructed by inserting a p53-coding sequence into pSG5 vector. All sequences amplified by PCR were confirmed by complete sequencing.
Cell Culture and Transient Transfection-COS-7 and human renal cell carcinoma 786-O cell lines were maintained in Dulbecco's modified Eagle's medium containing penicillin (25 units/ml), streptomycin (25 g/ml), and 10% fetal bovine serum. Transient transfection was performed using SuperFect (Qiagen) transfection solution according to manufacturer's protocol. For examining the degradation of VDU1 protein in COS-7 cells, we transiently transfected pEGFP-C3-hVDU1 (1.5 g) and pCMX-VHL19 (3 g) into COS-7 cells in 60-mm diameter plastic dishes. After 36 h of incubation, some cells were treated with MG132 (5 M, Calbiochem) for 6 h. For 786-O cells, the 100-mm diameter dishes of cells were transfected with a total of 10 g of DNA/ transfection (5 g of each plasmid and, when necessary, supplemented with empty pCMX vector to a total of 10 g of DNA). 36 h after transfection, cells from each transfection were divided equally into multiple 60-mm dishes, allowed to grow overnight, and then treated with either cycloheximide (100 g/ml, Sigma) for various time points or MG132 for 6 h.
Northern Blotting and Immunoblotting-The blot containing ϳ2 g of poly(A) RNA from human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas was purchased from CLONTECH and hybridized with 32 P-labeled hVDU1 cDNA. The blot was subsequently probed with a ␤-actin cDNA probe. Anti-GST, anti-6ϫ His, anti-ubiquitin, anti-␤-actin, and anti-GFP monoclonal antibodies were obtained from Santa Cruz Biotechnologies. Anti-VHL monoclonal antibody was purchased from PharMingen. Samples were resolved by SDS-PAGE gel and transferred to nitrocellulose membrane (Amersham Biosciences, Inc.) or polyvinylidene difluoride membrane (Millipore) for subsequent immunoblotting.
GST Pull-down Assay-Overnight cultures of BL21 cells transformed with wild-type, truncated, and mutant VHL GST fusion proteins were diluted 1:100 in a Luria-Bertani medium plus ampicillin and cultured at 30°C until A 600 reached 0.8. The fusion proteins were then induced with isopropyl-1-thio-␤-D-galactopyranoside and purified using glutathione-Sepharose 4B MicroSpin columns (Amersham Biosciences, Inc.). The amounts of GST or GST fusion proteins were quantitated using the Bradford assay (Bio-Rad). The same amounts of GST or GST fusion proteins were added into glutathione-Sepharose 4B MicroSpin columns and incubated for 3 h at 4°C. After the columns were washed three times, 5 l of in vitro translated [
35 S]methionine-labeled hVDU1 were added into each of the reactions and incubated at 4°C for 3 h. After being washed five times, the proteins were eluted by glutathione elution buffer, and 20 l of eluted protein were resolved on a 5% SDS-PAGE gel followed by autoradiography.
In Vitro and in Vivo Co-immunoprecipitation-An in vitro coupled reticulocyte transcription and translation system (Promega) with [ 35 S]methionine was used to generate recombinant proteins. For each immunoprecipitation sample, 10 l of protein A/G-agarose (Santa Cruz Biotechnologies) were precleared by mixing with 1 mg of mouse IgG at 4°C for 3 h mixed with 5 l of each radiolabeled in vitro translation product, 10 l of antibody, and 470 l of co-immunoprecipitation buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM dithiothreitol, 5 g/ml aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, and 0.1% Tween 20). The mixture was incubated at 4°C for 3 h in a shaker and washed three times. Bound proteins were eluted by boiling for 3 min in 1ϫ SDSloading buffer and separated on an 8% SDS-PAGE gel followed by autoradiography. For in vivo co-immunoprecipitation assays, COS-7 cells were transfected with 5 g of each plasmid pEGFP-C3-hVDU1 and/or pCMX-VHL19. 36 h after transfection, cells were treated with MG132 for 6 h and washed with ice-cold phosphate-buffered saline, lysed, and centrifuged at 14,000 ϫ g for 15 min. The supernatants were precleared by adding 100 l of protein A/G-agarose bead slurry/1 ml of cell lysate and incubated at 4°C for 10 min. Anti-VHL monoclonal antibody was added into the cell lysates and incubated for 2 h at 4°C. 30 l of protein A/G-agarose were then added into the mixture followed by rotation at 4°C for 3 h being spun down and washed three times. The precipitates were resolved on an 8% SDS-PAGE gel and blotted with anti-GFP antibody.
Mammalian Two-hybrid Assay-pM-VHL19, pVP16-hVDU1, and pG5CAT were co-transfected into COS-7 cells with a constant amount of a second reporter, pCMV-GAL4, for normalizing the transfection efficiency. After 24 h, cells were harvested and lysed. The lysates were used for radioactive chloramphenicol acetyltransferase assay to demonstrate the interaction between the two proteins.
In Vivo and in Vitro Deubiquitination Assay-For in vivo deubiquitination assay, pDEST14-hVDU1 or pDEST17-hVDU1 together with pA-CYC-184-Ub-GST was co-transformed into E. coli BL21 (DE3) cells (Stratagene). The cells were grown in Luria-Bertani medium to A 600 of 0.8 and induced with isopropyl-1-thio-␤-D-galactopyranoside for 3 h at 30°C, harvested by centrifugation at 5000 ϫ g for 20 min, lysed in phosphate-buffered saline by six times of sonication, and centrifuged for 20 min at 14,000 ϫ g. The supernatant was loaded onto a 12% SDS-PAGE gel followed by immunoblotting. For in vitro deubiquitination assay, 6ϫ His tag-fused hVDU1 was purified from E. coli BL21(DE3) cells transformed with the pET28c-hVDU1 using a Ni-NTA spin column (Qiagen). E. coli BL21(DE3) cells transformed with the empty pET28c was lysed and purified using Ni-NTA spin column. The eluted solution was used as negative control (see Fig. 4A , 6ϫ His tag). hVDU1 protein was also expressed as 6ϫ His tag fusion protein in COS-7 cells by transient transfection of pcDNA4c-hVDU1. Ubiquitin-GST fusion protein was purified from E. coli BL21 cells transformed with the pGEX-3X-Ub using glutathione-Sepharose 4B MicroSpin column. Purified ubiquitin-GST fusion protein and 6ϫ His tag-fused hVDU1 protein were incubated together in the deubiquitinating buffer (20 mM TrisHCl, pH 7.5, 5 mM MgCl 2 , 2 mM dithiothreitol) at 30°C for 1 h. Yeast lysates were used as a positive control. The reaction products were run on a 12% SDS-PAGE gel followed by immunoblotting.
In Vitro Ubiquitination Assay-The method for in vitro ubiquitination assay described by Cockman et al. (16) was used in our experiments. COS-7 or 786-O cells were washed twice with cold hypotonic extraction buffer (20 mM Tris, pH 7.5, 5 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol). Crude extracts were centrifuged at 10,000 ϫ g for 10 min at 4°C and stored in aliquots at Ϫ70°C. Ubiquitination assays were carried out at 30°C in a total volume of 40 l containing 3 l of [ 35 S]methionine-labeled hVDU1 or p53, 2 l of programmed reticulocyte lysate, 27 l of cell extract, 4 l of 10ϫ ATP-regenerating system (20 mM Tris, pH 7.5, 10 mM ATP, 10 mM magnesium acetate, 300 mM creatine phosphate, 0.5 mg/ml creatine phosphokinase), 4 l of 5 mg/ml ubiquitin (Sigma), and 1 l of 150 M ubiquitin-aldehyde (Calbiochem). For pVHL reconstitution experiments, the same amount of [
35 S]methionine-labeled wild-type or mutated pVHL19 2 was preincubated with the reaction mixture at room temperature for 5 min prior to the addition of substrate. Aliquots were removed at indicated times, mixed with SDS sample buffer, and analyzed by SDS-PAGE gel and autoradiography.
RESULTS
Yeast Two-hybrid Screening for pVHL-interacting ProteinsAfter screening 5.5 ϫ 10 6 clones, two of our positive cDNA clones were identical and ϳ2.5 kb in length. DNA sequencing revealed that these two clones encoded 402 amino acids followed by a 1.3-kb 3Ј-untranslated region and matched to an uncharacterized partial cDNA sequence (GenBank TM accession number AB029020). A yeast two-hybrid assay using independent co-transformation of the bait vector and these candidate clones followed by growth selection and a ␤-galactosidase assay further confirmed the interaction between pVHL and these candidate clones. We designated this gene as VHL-interacting deubiquitinating enzyme 1 (VDU1) based on sequence analysis.
Completion of Full-length Human and Mouse VDU1 cDNAs-Using 5Ј-and 3Ј-RACE-PCR method, we determined the full-length cDNA sequence of hVDU1. We found two hVDU1 mRNA species with differences at their 5Ј regions presumably resulting from RNA alternative splicing. hVDU1 Type I cDNA (GenBank TM accession number AF383172) contains 4502 nucleotides and encodes an open reading frame of 942 amino acids with a predicted molecular mass of 107 kDa. Multiple in-frame stop codons are present in hVDU1 Type I mRNA, indicating that the full-length coding region has been obtained. hVDU1 Type II mRNA (GenBank TM accession number AF383173) (4323 nucleotides) contains the same 5Ј end as Type I but lacks a 179-bp exon in the 5Ј region and encodes an open reading frame of 911 amino acids with a predicted molecular mass of 103 kDa. The initiation codon of Type II corresponds to the second methionine codon in hVDU1 Type I, and no in-frame stop codon exists in its 5Ј-untranslated region. We 2 In vitro translated protein from pcDNA4c-VHL19, pcDNA4c-VHL19-P81S, and pcDNA4c-VHL19-R82P by TNT system (Promega), the amount of these proteins were estimated using ImageQuant software by quantitating the radioactivity. also isolated the mouse homologue (mVDU1) using mouse testis and embryo cDNAs as templates. As in the 5Ј-untranslated region of hVDU1 Type II, no in-frame stop codon was present in the 5Ј-untranslated region of mVDU1. The mVDU1 (GenBank TM accession number AF383174) consists of 909 amino acids, which corresponds to hVDU1 Type II. The putative amino acid sequences of hVDU1 and mVDU1 are shown in the Fig. 1A . The alignment of amino acid sequences shows that the mVDU1 has a 92% homology with hVDU1 Type II. After searching the PROSITE data base, two ubiquitin C-terminal hydrolase domains, Ϫ1 and Ϫ2, crucial for the deubiquitinating activity of deubiquitinating enzymes, were identified in human and mouse VDU1. Northern blot analysis showed that hVDU1 mRNA was expressed at the highest levels in brain, kidney, heart, and placenta tissues but at lower levels in the liver, lung, pancreas, and skeletal muscle (Fig. 1B) . The size of hVDU1 mRNA is ϳ4.5 kb, and only this single band is shown on the blot (Fig. 1B) , which suggests that if alternative splicing occurs, only small differences may exist in VDU1 mRNAs. This result also further supports our completion of the full-length cDNA cloning of VDU1. Because the extra amino acids in the N terminus of hVDU1 Type I were not conserved in mVDU1 based on our current findings, hVDU1 Type II was constructed into different expression vectors for the studies described below.
hVDU1 Binds to pVHL-The association of full-length hVDU1 with pVHL was tested in vitro using a GST pull-down assay. The 35 S-labeled hVDU1 specifically bound to the GSTpVHL19-(54 -213) fusion protein but not to the GST alone ( Fig.  2A) , indicating a physical association between these two proteins in vitro. The association of hVDU1 with pVHL was also tested by in vitro co-immunoprecipitation. The 35 S-labeled hVDU1 and c-Myc-fused pVHL19-(54 -213) were transcribed and translated in vitro. After interacting with c-myc-fused pVHL, hVDU1 was precipitated by an anti-c-Myc antibody (Fig. 2B) . To determine whether pVHL and hVDU1 could interact in mammalian cells, a co-transfection of pM-pVHL-(54 -213) and pVP16-hVDU1 into COS-7 cells was performed, which revealed that the expression of chloramphenicol acetyltransferase enzyme was stimulated by the interaction between these two proteins (Fig. 2C) . The interaction between hVDU1 and pVHL was also tested by in vivo co-immunoprecipitation. In this experiment, pEGFP-C3-hVDU1 and pCMX-pVHL were co-transfected into COS-7 cells. As shown in Fig. 2D , GFPhVDU1 could be co-precipitated by an anti-VHL antibody (Fig.  2D) . These in vitro and in vivo experiments strongly support our conclusion that the hVDU1 protein is a pVHL-interacting partner.
The pVHL ␤-domain Is Required for hVDU1 Binding-To further determine the hVDU1-interacting region in pVHL, GST pull-down assay was performed with pVHL fragments covering different regions. GST-VHL-(54 -213), GST-VHL-(54 -100), and GST-VHL-(54 -83), but not GST-VHL-(80 -213) and GST-(93-213), could bind to the in vitro translated hVDU1 protein (Fig. 3A) . These results suggest that hVDU1 interacts with pVHL from residues 54 to 83. This region is in the pVHL ␤-domain, which is responsible for substrate recognition for ubiquitination and degradation. Many missense mutations found in VHL disease or renal cell carcinomas occur in this region. We further tested the interactions between hVDU1 and several common VHL mutants that harbor naturally occurring mutations in the ␤-domain and ␣-domain. Our results showed that pVHL mutants harboring the mutations in the ␤-domain (F76I, N78S, P81S, and R82P) disrupted the interactions between pVHL and hVDU1. The mutant P86H, located in the ␤-domain of pVHL but not in the hVDU1-interacting region of pVHL, did not affect the interaction between hVDU1 and pVHL. VHL mutants, R167Q and R167W, which harbor the mutations in the ␣-domain were able to bind to hVDU1 albeit at a reduced capacity (Fig. 3B) .
hVDU1 Exhibits Ubiquitin Cleavage Activity-To determine whether VDU1 indeed has deubiquitinating activity, in vitro and in vivo deubiquitination assays were performed. These two assays have been used to establish the basic enzymatic activity of USPs (23, 24) . For an in vitro deubiquitination assay, hVDU1 was expressed as 6ϫ His tag-fused protein in bacteria and in COS-7 cells. The proteins were purified by Ni-NTA spin columns. The ubiquitin cleavage activity was assayed against the artificial ubiquitin-GST fusion protein. Whereas the 6ϫ His tag alone exhibited no cleavage of the Ub-GST fusion protein, the 6ϫ His tag fused to hVDU1 was able to cleave Ub-GST into ubiquitin and GST. The yeast extract harboring deubiquitinating activity was used as a positive control. This deubiquitinating activity of hVDU1 could completely be abrogated by ubiquitin-aldehyde, a specific inhibitor of deubiquitinating enzymes (Fig. 4A) . In the in vivo deubiquitination assay, co-transformations of pDEST14-hVDU1 or pDEST17-hVDU1 with pACYC-184-Ub-GST (substrate), respectively, revealed that ubiquitin-GST fusion protein could be cleaved into GST and ubiquitin by either native hVDU1 or 6ϫ His tag-fused hVDU1 protein.
In the negative control, the empty pDEST17 vector and pACYC184-Ub-GST were co-transformed into bacteria, and Ub-GST fusion protein was intact (Fig. 4B) .
hVDU1 Binds to VHL Elongin C-Elongin B Complex-To determine whether VDU1 can be recruited into the VCB complex, an in vitro co-immunoprecipitation assay was performed. hVDU1 (pSG5-hVDU1), FLAG-VHL (pCMX-VHL19), EB (pcDNA3-EB), and 6ϫ His-fused EC (pcDNA4-EC) were prepared in a reticulocyte-coupled transcription-translation system. Co-immunoprecipitation was performed using anti-6ϫ His tag antibody. When pVHL was present, hVDU1 could be precipitated by an anti-6ϫ His tag antibody along with pVHL, EC, and EB, but when pVHL was absent, 6ϫ His tag antibody was able to precipitate EC and EB but not hVDU1. These results suggest that hVDU1 can be recruited into VCB complex by pVHL (Fig. 5) .
Ubiquitination of hVDU1 Is pVHL-dependent-To test whether hVDU1 can be ubiquitinated by pVHL E3 ubiquitin ligase, we performed a series of in vitro ubiquitination assays. Initially, cell extracts from COS-7 were incubated with [ 35 S]methionine-labeled hVDU1. Incubation with the extract alone converted the hVDU1 substrate to a slower migrating form (Fig. 6A) , indicating that the hVDU1 could be polyubiquitinated. To determine the role of pVHL in hVDU1 ubiquitination, we performed similar assays using extracts from 786-O cells. This kidney cancer cell line contains a single VHL allele with a frameshift mutation at codon 104 (3), which results in a loss of binding to EC. Our results showed that the addition of wild-type pVHL to the 786-O cell extracts resulted in the ubiquitination of hVDU1, whereas without wild-type pVHL, the 786-O cell extracts were unable to ubiquitinate hVDU1 (Fig.  6B) . This pVHL-dependent ubiquitination was also specific to hVDU1, because the ubiquitination of p53, which was tested under the same conditions, was not affected by the addition of pVHL (Fig. 6C) . Furthermore, this pVHL-dependent ubiquitination process was diminished when using naturally occurring VHL missense mutations in its ␤-domain that disrupt the interaction between hVDU1 and pVHL (Fig. 6D) .
pVHL Mediates the Degradation of hVDU1 by Proteasome-We have demonstrated that hVDU1 can be ubiquitinated in a pVHL-dependent manner. To test whether this ubiquitination mediated by pVHL will result in a rapid turnover of VDU1 protein, we examined the degradation of hVDU1 protein in COS-7 and 786-O cells. COS-7 cells were transiently transfected with pEGFP-hVDU1 together with or without pCMX-VHL19. Transient co-expression of GFP-hVDU1 and pVHL results in a reduction of hVDU1 protein signal (Fig. 7A) , indicating that pVHL might be the limiting factor in hVDU1 degradation. pVHL-induced reduction of hVDU1 protein level was inhibited by treatment of the cells with the proteasome inhibitor MG132 (Fig. 7A) . Both the co-transfection of pVHL and treatment with MG132 had no effect on the expression level of GFP alone (data not shown). To further evaluate the effect of pVHL on the degradation of hVDU1 protein, we also transiently transfected pEGFP-hVDU1 into 786-O cells with or without co-transfection with pVHL. hVDU1 protein was extremely stable in the group without co-transfection of pVHL during cycloheximide treatment, and MG132 did not signifi- FIG. 3. hVDU1 binding site on pVHL. A, mapping the hVDU1-interacting region in pVHL. Five microliters of in vitro translated hVDU1 protein were incubated with beads coated with GST, GST-VHL54 -83, GST-VHL54 -100, GST-VHL80 -213, GST-VHL93-213, and GST-VHL54 -213 fusion proteins. The bound proteins were eluted and analyzed on a SDS-PAGE gel. B, effect of tumor-associated missense mutations in the ␤-domain of pVHL on the interaction between hVDU1 and pVHL. Five microliters of in vitro translated hVDU1 protein were incubated with beads coated with equal amounts of GST, GST-VHL54 -213 and the indicated GST-VHL mutant fusion proteins (quantitated by the Bradford assay).
FIG. 4. Deubiquitinating activity of hVDU1.
A, in vitro deubiquitination assay. Ub-GST was incubated with 6ϫ His alone ((His)6), yeast extract (Yeast Lysate), 6ϫHis-hVDU1 ((His)6-hVDU1), 6ϫ HishVDU1 together with ubiquitin-aldehyde (Ub-A1). B, in vivo deubiquitination assay. The reactions were electrophoresed and followed by Western blots with anti-GST and anti-ubiquitin antibody, respectively. Note that hVDU1 can cleave Ub-GST, and ubiquitin-aldehyde can inhibit this deubiquitinating activity of hVDU1. Both hVDU1 and 6ϫ His tag hVDU1 possess deubiquitinating activity. cantly increase the level of hVDU1 protein (Fig. 7B ). In contrast, hVDU1 protein was unstable when co-transfected with pVHL. The cycloheximide treatment led to a significant decrease in hVDU1 protein level, but strikingly, MG132 treatment restored the hVDU1 protein level (Fig. 7B) . Taken together, these data demonstrated that hVDU1 protein was undergoing proteasome-dependent degradation in a pVHL-dependent manner, indicating that hVDU1 protein is a downstream target of pVHL E3 ligase for ubiquitination and rapid degradation by proteasome.
DISCUSSION
In addition to ubiquitinating enzymes, the ubiquitination process is also involved with another class of enzymes, deubiquitinating enzymes (25) . These enzymes are extremely divergent, showing very little amino acid sequence similarity with exception of the short consensus sequences surrounding the cysteine (Cys box) and histidine residues (His box), which are highly conserved among all deubiquitinating enzymes. These conserved Cys and His boxes are crucial for the deubiquitinating activity of these enzymes (25) . The high degree of divergence in this protein family indicates that different family members may have unique biochemical properties, substrate specificities, and cellular localizations (25) . Possible functions of deubiquitinating enzymes include the following (25): (a) proteolytic processing of primary ubiquitin gene products to generate ubiquitin and the ribosomal proteins L40 and S27a, (b) disassembly of the polyubiquitin chain from target protein or its remnants during and after degradation, (c) salvage of ubiquitin from non-functional linkages arising from reactions between thiol ester intermediates and small intracellular compounds such as thiols or amines, and (d) rescuing proteins from degradation by removing ubiquitin from protein substrates, therefore competing or counteracting with the ubiquitin-conjugating system.
In this study, we have identified a novel pVHL-interacting deubiquitinating enzyme, VDU1. Based on sequence homology, VDU1 belongs to the USP family. As demonstrated in our experiments, hVDU1 can cleave model ubiquitin substrates, and this basic enzymatic function is consistent with the presence of conserved Cys and His boxes in its molecular structure. Mutagenesis studies have demonstrated that these two conserved motifs play important roles in ubiquitin cleavage activity. USP family members usually contain a core region of approximately 450 amino acids delineated by the Cys and His boxes, an N-terminal extension, a C-terminal extension, and variable sequences in the core region. The functions of these divergent sequences remain poorly understood. These extensions and insertions might be involved in the substrate recognition, subcellular localization of the enzymes, and proteinprotein interaction. Some of the USP family members also have isoforms. For example, USP-t, a USP enzyme primarily expressed in the testis, has two isoforms sharing the same core region and C terminus but with distinct N termini. These two different N termini not only target the two isoforms to distinct subcellular compartments but also confer different enzymatic activity (26) . Human VDU1 also has two major isoforms (Type I and Type II) with distinct N termini, but this feature is not conserved in mouse VDU1 based on our current data. There are other putative hVDU1 isoforms generated by alternative splicing of its mRNA that result in the deletion of short stretches of amino acids between the Cys box and His box. 3 The significance of hVDU1 isoforms is currently under investigation in our laboratory. VDU1, like the VHL gene, is widely expressed in different tissues including VHL disease-affected tissues, such as brain, kidney, and pancreas. When overexpressed in cells, hVDU1 type II protein is localized in the cytoplasm, 3 where the pVHL-mediated ubiquitination occurs.
Based on the structure of the VCB complex revealed by Stebbins et al. (14) , the pVHL molecule folds into two major domains. One is the ␣-domain (residues 155-192), an ␣-helix, which forms the principal contact with EC. The other one is a 35 S-Labeled hVDU1 was used as a substrate in reactions of different composition with and without ATP regeneration system. The positions of the non-ubiquitinated and ubiquitinated hVDU1 are indicated. B, pVHL-dependent hVDU1 ubiquitination.
35 S-Labeled hVDU1 was incubated at 30°C for the indicated times in reactions consisting of 786-O cell extracts, ATPregenerating system, ubiquitin, and ubiquitin-aldehyde (UbA1). Ubiquitination of hVDU1 was only found in the presence of pVHL (in vitro translated protein from pcDNA4-VHL19). C, pVHL-dependent in vitro ubiquitination exhibits target specificity. pVHL-independent ubiquitination of p53 was observed. D, the effect of several VHL mutations on the hVDU1 ubiquitination. No ubiquitination was detected in the presence of pVHL mutants (in vitro translated proteins from pcDNA4c-VHL19-P81S and pcDNA4c-VHL19-R82P). larger ␤-domain consisting of seven ␤-strands (residues 63-154) and one ␣-helix (residues 193-204). Approximately 50% of naturally occurring pVHL mutations locate on the ␣-domain, and the remaining mutations map to the ␤-domain, which suggests that both domains are important to the tumor suppressor functions of pVHL. Recently, Ohh et al. (15) has demonstrated that pVHL binds directly to HIF through its ␤-domain and targets HIF for ubiquitination (15) . Mutations in either the pVHL ␣-or ␤-domain may cause an overaccumulation of HIF in affected cells, which helps explain why highly vascularized tumors develop in VHL disease. In this report, we have demonstrated that hVDU1 also binds to the ␤-domain of pVHL. The C-terminal truncation and missense mutants retained the interaction between hVDU1 and pVHL, whereas four naturally occurring mutations in the ␤-domain identified from VHL disease, F76I, N78S, P81S, and R82P, impaired the interaction between hVDU1 and pVHL. By analogy with HIF1␣, this finding suggests that the loss of interaction between hVDU1 and pVHL might be relevant to the tumorigenesis of VHL-related tumors. Our current data suggest that hVDU1 is a downstream substrate of the VCB E3 ligase for ubiquitination and rapid degradation. Direct interaction between hVDU1 and pVHL is required for ubiquitination of hVDU1. Our data also provide further evidence that the ␤-domain of pVHL acts as the recognition site in the VCB-E3 ubiquitin ligase complex. The fact that several common mutations in the ␤-domain of pVHL identified in clinical VHL disease result in a loss of interaction between VDU1 and pVHL, therefore preventing ubiquitination of VDU1 (loss of function), suggests a physiological relevance of VDU1 as a substrate of VCB-E3 ubiquitin ligase complex. If pVHL is mutated whether in the ␣-or ␤-domain, VDU1 would not be ubiquitinated and degraded properly. This could lead to an accumulation of VDU1 proteins in the cells. In light of the deubiquitinating activity and other possible functions of the USP enzymes (25), VDU1 might be another important pVHL-interacting protein. Firstly, it is possible that through target ubiquitination and degradation of VDU1, pVHL might be able to down-regulate a specific deubiquitinating pathway mediated by VDU1, therefore promoting the degradation of proteins regulated by VDU1. Secondly, it is also possible that VDU1 might deubiquitinate the ubiquitinated downstream targets of pVHL E3 ligase by removing the polyubiquitin chain from these ubiquitinated proteins. Further investigation to reveal the detailed biochemical and physiological functions of this enzyme will help us to understand its role in the tumorigenesis of VHL-related tumors.
